3-(5-dimethylcarbamoylpent-1-ynyl)-N-(2-hydroxy-1-methylethyl)benzamide | 863713-68-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(5-dimethylcarbamoylpent-1-ynyl)-N-(2-hydroxy-1-methylethyl)benzamide
• 英文别名: 3-(5-dimethylcarbamoyl-pent-1-ynyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide；3-(5-Dimethylcarbamoyl-pent-1-ynyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide；3-[6-(dimethylamino)-6-oxohex-1-ynyl]-N-(1-hydroxypropan-2-yl)benzamide
• CAS: 863713-68-2
• 化学式: C₁₈H₂₄N₂O₃
• 分子量: 316.4
• InChiKey: HZSJCMOFKMZACZ-UHFFFAOYSA-N

物化性质

• 沸点：
  543.4±45.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5-dimethylcarbamoylpent-1-ynyl)-N-(2-hydroxy-1-methylethyl)benzamide 生成 非维匹仑
  参考文献：
  名称：

  Modulator

  摘要：

  本公开涉及式（I）的化合物或其药学上可接受的盐，其中Z从OH，NHCH2CH2F，NHCH（Me）CH2OH和NHCH2CH2OH中选取；X是烷基，烯基或炔基，每个基团可以选择性地被一个或多个取代基所取代，所述取代基从烷基，COOH，CO2-烷基，烯基，CN，NH2，羟基，卤素，烷氧基，CF3和硝基中选择；Y是极性官能团，从OH，NO2，CN，COR3，COOR3，NR3R4，CONR3R4，SO3H，SO2—R3，SO2NR3R4和CF3中选择，其中R3和R4各自独立地是氢或烃基团；A是苯基或吡啶基；B是（CH2）n，其中n为0；但要求：当A是苯基，且Z为OH时，X-Y不是C≡C-（CH2）2CO2H，C≡C-（CH2）2CO2Me，（CH2）4CO2H。提供了这种化合物作为治疗肌肉疾病，胃肠疾病，或控制痉挛或震颤的药物的用途。

  公开号：

  US09120723B2
• 作为产物：
  描述：

  盐酸二甲胺 在 氯甲酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.25h， 以96%的产率得到3-(5-dimethylcarbamoylpent-1-ynyl)-N-(2-hydroxy-1-methylethyl)benzamide
  参考文献：
  名称：

  [EN] MODULATORS OF CANNABINOID RECEPTORS
  [FR] MODULATEUR

  摘要：

  公开号：

  WO2005080316A3

文献信息

• [EN] COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA MODULATION DU CANAL BK
  申请人：CANBEX THERAPEUTICS LTD

  公开号：WO2016128771A1

  公开（公告）日：2016-08-18

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR16 or NR17R18; R16 is H or alkyl; R17 is H or alkyl; R18 is alkyl or cycloalkyl, each of which is optionally substituted by one or more substituents selected from OH, halogen and COOR11; X is a group selected from -C≡C-

  本发明涉及一种式I的化合物，或其药学上可接受的盐、溶剂或前药，其中：Z为OR16或NR17R18；R16为H或烷基；R17为H或烷基；R18为烷基或环烷基，每个烷基或环烷基可选择地被一个或多个OH、卤素和COOR11取代；X为从-C≡C-<(CH2)P-；-C
• [EN] PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS<br/>[FR] PROCÉDÉ
  申请人：UCL BUSINESS PLC

  公开号：WO2010116116A1

  公开（公告）日：2010-10-14

  The present invention relates to a process for preparing a compound of formula wherein: R2 is cycloalkyl or alkyl, each of which may be optionally substituted; Y is -CONR3R4, -CN or CO2R5; R3, R4 and R5 are each independently H or alkyl; n is 1 to 6; wherein said process comprising the steps of : (i) treating a compound of formula (IV), where R1 is alkyl, with a compound of formula (V) and forming a compound of formula (IIIb); (ii) treating said compound of formula (IIIb) with a compound of formula (Il) to form a compound of formula (I).

  本发明涉及一种制备化合物的过程，其化学式为其中：R2为环烷基或烷基，每种均可选择性地被取代；Y为-CONR3R4，-CN或CO2R5；R3、R4和R5分别独立地为H或烷基；n为1至6；其中所述过程包括以下步骤：(i) 用具有化学式（IV）的化合物处理化学式（V）的化合物，并形成化学式（IIIb）的化合物；(ii) 用化学式（IIIb）的化合物处理化学式（Il）的化合物，形成化学式（I）的化合物。
• Modulator
  申请人：CANBEX THERAPEUTICS LIMITED

  公开号：US09120723B2

  公开（公告）日：2015-09-01

  The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from OH, NHCH2CH2F, NHCH(Me)CH2OH and NHCH2CH2OH; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is phenyl or pyridyl; and B is (CH2)n where n is 0; with the proviso that: (i) when A is phenyl, and Z is OH, X—Y is other than C≡C—(CH2)2CO2H, C≡C—(CH2)2CO2Me, (CH2)4CO2H. Uses of such compounds as medicaments for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors are provided.

  本公开涉及式（I）的化合物或其药学上可接受的盐，其中Z从OH，NHCH2CH2F，NHCH（Me）CH2OH和NHCH2CH2OH中选取；X是烷基，烯基或炔基，每个基团可以选择性地被一个或多个取代基所取代，所述取代基从烷基，COOH，CO2-烷基，烯基，CN，NH2，羟基，卤素，烷氧基，CF3和硝基中选择；Y是极性官能团，从OH，NO2，CN，COR3，COOR3，NR3R4，CONR3R4，SO3H，SO2—R3，SO2NR3R4和CF3中选择，其中R3和R4各自独立地是氢或烃基团；A是苯基或吡啶基；B是（CH2）n，其中n为0；但要求：当A是苯基，且Z为OH时，X-Y不是C≡C-（CH2）2CO2H，C≡C-（CH2）2CO2Me，（CH2）4CO2H。提供了这种化合物作为治疗肌肉疾病，胃肠疾病，或控制痉挛或震颤的药物的用途。
• MODULATOR
  申请人：Okuyama Masahiro

  公开号：US20100144876A1

  公开（公告）日：2010-06-10

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR 1 or NR 1 R 2 wherein each of R 1 and R 2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO 2 -alkyl, alkenyl, CN, NH 2 , hydroxy, halo, alkoxy, CF 3 and nitro; Y is a polar functional group selected from OH, NO 2 , CN, COR 3 , COOR 3 , NR 3 R 4 , CONR 3 R 4 , SO 3 H, SO 2 —R 3 , SO 2 NR 3 R 4 and CF 3 , where each of R 3 and R 4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH 2 ) n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C≡—C—(CH 2 ) 2 CO 2 H, meta-C≡—C—(CH 2 ) 2 OH, meta-C≡C—(CH 2 ) 2 CO 2 Me, meta-(CH 2 ) 4 CO 2 H, ortho-CH 2 CO 2 H, ortho-(CH 2 ) 2 CO 2 H and ortho-(CH 2 ) 4 CO 2 H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C≡C—(CH 2 ) 4 OH. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Z为OR1或NR1R2，其中R1和R2各自独立地为H或烃基；X为可选地由烷基，COOH，CO2-烷基，烯基，CN，NH2，羟基，卤素，烷氧基，CF3和硝基中的一个或多个取代的烷基，烯基或炔基基团；Y为从OH，NO2，CN，COR3，COOR3，NR3R4，CONR3R4，SO3H，SO2—R3，SO2NR3R4和CF3中选择的极性官能团，其中R3和R4各自独立地为H或烃基；A为可选地取代的芳基或杂环基团；B为（CH2）n，其中n为0、1、2、3、4或5；但有以下规定：（i）当A为苯基，n为0，且Z为OH时，X—Y不是间位-C≡—C—（CH2）2CO2H，间位-C≡—C—（CH2）2OH，间位-C≡C—（CH2）2CO2Me，间位-（CH2）4CO2H，邻位-CH2CO2H，邻位-（CH2）2CO2H和邻位-（CH2）4CO2H；（ii）当A为苯基，n为0，且Z为OMe时，X—Y不是间位-C≡C—（CH2）4OH。本发明的进一步方面涉及使用这些化合物制备治疗肌肉障碍，胃肠障碍或控制痉挛或震颤的药物。
• PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS
  申请人：Selwood David

  公开号：US20120101301A1

  公开（公告）日：2012-04-26

  The present invention relates to a process for preparing a compound of formula wherein: R 2 is cycloalkyl or alkyl, each of which may be optionally substituted; Y is —CONR 3 R 4 , —CN or CO 2 R 5 ; R 3 , R 4 and R 5 are each independently H or alkyl; n is 1 to 6; wherein said process comprising the steps of: (i) treating a compound of formula (IV), where R 1 is alkyl, with a compound of formula (V) and forming a compound of formula (IIIb); (ii) treating said compound of formula (IIIb) with a compound of formula (I1) to form a compound of formula (I).

  本发明涉及一种制备以下式子化合物的方法：其中：R2是环烷基或烷基，每个基团都可以选择性地被取代；Y是—CONR3R4，—CN或CO2R5；R3、R4和R5分别是H或烷基；n为1到6；其中所述方法包括以下步骤：(i)用式子(IV)化合物（其中R1是烷基）处理式子(V)化合物，形成式子(IIIb)化合物；(ii)用式子(I1)化合物处理所述式子(IIIb)化合物，形成式子(I)化合物。